#	Pagina
attuale pagina	/open-h2020/projects/197177/index.html

Opendata, web and dolomites

ChemoPredict

Predictive in vitro diagnostics test for individualized tailoring of chemotherapy in primary breast cancer

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ChemoPredict project word cloud

Explore the words cloud of the ChemoPredict project. It provides you a very rough idea of what is the project "ChemoPredict" about.

patient anthracycline decide leaders overtreatment plan standard judged comprehensively entrance entering elaborated guidelines trial prototype 79 assay inclusion exhibits data finher ce patients health generate validated highest deciding marked directive diagnostic perspective serious breast interviewed taxane ec personalized regulatory feasibility care cancer extended 50 containing extend predictive initiated group regimens clinical treat strategies sividon outcome innovation reimbursement retrospective strategy risk ivd 98 reduce countries stratify training chemotherapy prospective market opinion medicine chemopredict 919 started impairment innovative boards saving tool business clinically taxanes advisory validation avoiding chemotherapies analytical

Project "ChemoPredict" data sheet

The following table provides information about the project.

Coordinator	SIVIDON DIAGNOSTICS GMBH Organization address address: NATTERMANNALLEE 1 GEB S19 city: KOLN postcode: 50829 website: www.sividon.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.sividon.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-07-01 to 2015-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	SIVIDON DIAGNOSTICS GMBH SIVIDON DIAGNOSTICS GMBH Organization address address: NATTERMANNALLEE 1 GEB S19 city: KOLN postcode: 50829 website: www.sividon.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (KOLN)	coordinator	50˙000.00

Map

Project objective

SIVIDON established a prototype diagnostic assay - the ChemoPredict test - to stratify high-risk breast cancer patients and to help in deciding whether to treat the patient with standard anthracycline-based chemotherapy without taxane or taxane-containing regimens. ChemoPredict was clinically validated in a large clinical phase III trial (FinHer) with 919 patients using a prospective-retrospective approach. The existing training and validation studies of ChemoPredict provided evidence that the assay can reduce the number of taxane-based chemotherapies within the test’s target group by about 50% without impairment of outcome of the patients. Thus, the use of the assay in breast cancer care will result in a more specific use of taxanes and a reduction of overtreatment thus avoiding serious side effects in patients and saving costs for the health care system. SIVIDON’s aim for the overall innovation project is to extend clinical and analytical validation data, to develop ChemoPredict as a CE-marked IVD test according to IVD directive 98/79/EC and to bring this test as a tool for personalized medicine into the European market. The objective of the feasibility study is to generate an elaborated business plan including detailed market analyses for ChemoPredict. Several key opinion leaders will be interviewed to get their perspective on the application, the inclusion into clinical guidelines and market entrance of the innovative predictive test. Phase I will be also used to decide on an extended clinical validation strategy to ensure that the ChemoPredict assay exhibits the highest clinical evidence level. Advisory boards will be initiated, opportunities for entering clinical guidelines will be judged and reimbursement concepts in European countries will be assessed. Regulatory issues will be comprehensively evaluated to decide on the best product development strategy, a detailed product development plan will be generated and phase 0 development strategies will be started.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHEMOPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHEMOPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

PD_Pal (2019)

Palliative care in Parkinson’s disease

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development